The Oncotype DX® 21-gene Recurrence Score® result stratifies patients with breast cancer into low-, intermediate- and high-risk groups that correspond to the likelihood of recurrence after the initial diagnosis. At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the evidence of the predictive value of the Recurrence Score® result to guide decision making for adjuvant chemotherapy.
This content is supported by Genomic Health, Inc.
